DZ Bank

DZ Bank’s KalVista Pharmaceuticals KALV Stock Holding History

DZ Bank’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-40,636	Closed	-$385K	–	974
2018 Q1	$385K	Buy	+40,636	New	+$425K	﹤0.01%	834

Other funds holding KALV

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

DZ Bank's KALV Position: Q2 2018 in Review

DZ Bank sold out of KalVista Pharmaceuticals (KALV) in Q2 2018, closing a stake of 40,636 shares — an estimated $385K sold.

DZ Bank first reported a position in KALV in Q1 2018 and held it in 1 quarter. The position peaked at $385K in Q1 2018. 26 funds tracked by Wall St. Rank hold KALV as of Q2 2018.

DZ Bank reported no remaining KalVista Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 40,636 KalVista Pharmaceuticals shares in Q2 2018, an estimated $385K.
DZ Bank first reported a position in KalVista Pharmaceuticals in Q1 2018 and held it in 1 quarter.
DZ Bank's KalVista Pharmaceuticals position peaked at $385K in Q1 2018.
26 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.